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available upon presentation.
Conclusions: The Energy demonstrates very good results which were promising for
subgroups with diabetes, small vessels and even acute coronary syndrome. Utility of
such modern bare metal stent platforms is still relevant in the era of drug-eluting
stents.TCT-184
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Background: Late adverse events such as very late stent thrombosis (VLST) or late
target-lesion revascularization (TLR) have emerged as new problems after drug-
eluting stent implantation. However, there is a paucity of data from long-term follow-
up studies evaluating late adverse events after sirolimus-eluting stents (SES)
implantation in comparison with bare-metal stent (BMS) implantation.
Methods: Among 13058 consecutive patients undergoing ﬁrst percutaneous coronary
intervention in the CREDO-Kyoto registry Cohort-2, 5078 patients were treated with
SES only and 5392 patients were treated with BMS only. Median follow-up duration
was 1974 (inter-quartile range: 1700-2225) days.
Results: During 4-7 years follow-up after SES implantation, VLST and late TLR
beyond 1-year occurred constantly and without attenuation at 0.24%/year, and 2.0%/
year, respectively. Cumulative 7-year incidence of VLST was signiﬁcantly higher in
the SES group than in the BMS group (1.43% vs. 0.68%, P<0.0001). However, there
was no excess of all-cause death beyond 1-year in the SES group as compared with the
BMS group (20.8% vs. 19.6%, P¼0.91), although the cumulative incidence of sudden
death beyond 1-year was slightly but signiﬁcantly higher in the SES group than in the
BMS group (3.0% vs. 1.8%, P¼0.02). Cumulative 7-year incidences of late TLR and
clinically-driven late TLR were also signiﬁcantly higher in the SES group than in the
BMS group (12.0% vs. 4.1%, P<0.0001 and 8.5% vs. 2.6%, P<0.0001, respectively),
leading to signiﬁcant late catch-up of the SES group to the BMS group regarding the
cumulative incidence of over-all and clinically-driven TLR through 7-year (18.8% vs.
25.2%, and 10.6% vs. 10.2%, respectively). Clinical indication of late TLR in the SES
group included acute myocardial infarction (13.1%), unstable angina (8.1%), stable
angina (34.0%), asymptomatic ischemia (7.9%) and non-clinically driven (36.9%).
Conclusions: During 4-7 years follow-up after SES implantation, late adverse events
including VLST and late TLR continued to occur without attenuation of their inci-
dences. Late catch-up phenomenon of SES relative to BMS in terms of TLR was real
and should be the target for the development of drug-eluting stents.
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Background: Late target lesion revascularization (TLR) and stent thrombosis with
drug-eluting stents (DES) remain a concern, especially in the thrombogenic milieu
of acute coronary syndrome (ACS). This study aims to investigate the long-term
safety and efﬁcacy of everolimus- (EES) and zotarolimus-eluting stents (ZES)B60 JACC Vol 62/18/Suppl B j October 27–November 1, 2013to 1st-generation sirolimus-eluting stents (SES) and bare metal stents (BMS) in ACS
patients.
Methods:We identiﬁed 1612 patients presenting with ACS who received either BMS,
SES, ZES or EES. The primary end points were probable or deﬁnite stent thrombosis
(ST) and major adverse cardiovascular event (MACE) deﬁned as composite of all-
cause death, myocardial infarction, or TLR up to 3 years.
Results: The 3-year MACE was 44.9% in the BMS group versus 34.6% in the SES
group versus 21.8% in the ZES group and 18.5% in the EES group (p <0.001).
Mortality at 3 years was highest in the BMS group (36.7%) than in the SES, ZES or
EES groups (22.5% vs 12.9% vs 12%, respectively; p <0.001). The 30-day ST was
highest in the SES group (5.1%) compared to BMS group (1.4%), ZES group (2.3%)
and EES group (1.1%) (p <0.001).These ﬁndings were reﬂected at 3 years (7.5% vs
1.9% vs 2.3% vs 1.5%, respectively; p <0.001).
Conclusions: The newer drug-eluting stents, EES and ZES, have shown improved
rate of MACE over BMS and 1st-generation SES. In addition, ST rates up to 3 years in
EES and ZES were comparable to BMS in ACS patients.TCT-186
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Background: Patients with acute myocardial infarction (AMI) have had conﬂicting
results between drug-eluting stents (DES) and bare-metal stents (BMS). The aim of
this study was to compare 5-year outcomes between DES and BMS in Asian patients
after AMI with or without diabetes (DM).
Methods: This study enrolled 1137 consecutive AMI patients who received stent
implantation in a single tertiary medical center from 2004 to 2011. The patients were
divided into DES (N¼210, 60 DM patients) and BMS group (N¼927, 302 DM
patients)in the study. The 5-year outcomes were collected, including early thrombosis
events (< 1 month), late thrombosis events (1-12 months), very late thrombosis events
(>12 months), time to the occurrence of myocardial re-infarction and time to
cardiovascular death.
Results: The baseline characteristics and complication rates were not different
between BMS and DES study groups. BMS and DES had almost identical rate of early
thrombosis (0.9% vs 0%, p¼0.117), late thrombosis (2.2% vs 1.0%, p¼0.252) and
very late thrombosis (0.8% vs 0%, p¼0.207). The Kaplan-Meier analysis showed
there was no difference of 5-year myocardial re-infarction event rate and 5-year
cardiovascular survival between DES and BMS groups, whether DM or non-DM
patients (Please see Figure).j TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
Bifurcation treatment
(N= 362)
Zotarolimus-Eluting
Resolute stent
(N = 179)
Everolimus-Eluting
Xience V stent
(N = 183)
Difference
(95% CI) p value
Target vessel
failure
23 (12.8) 21 (11.5) 1.4 (-5.4 to 8.1) 0.69
Death
Any cause 9 (5.0) 4 (2.2) 2.8 (-1.0 to 6.7) 0.15
Cardiac cause 4 (2.2) 2 (1.1) 1.1 (-1.5 to 3.8) 0.40
Target vessel
related MI
Any 14 (7.8) 14 (7.7) 0.2 (-5.4 to 5.7) 0.95
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PMConclusions: This study demonstrated DES showed the same early, late and very late
thrombosis rate as BMS. In long term follow up, whether DM or non-DM patients,
DES had similar 5-year re-infarction rate and cardiovascular death as BMS in Asian
patients after AMI.
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Background: Polytetraﬂuoroethylene (PTFE)-covered stents have improved the in-
hospital clinical outcomes of patients with coronary perforation. However, there are
a few reports regarding their long-term outcomes.
Methods:We analyzed data that was prospectively collected from 17277 patients who
underwent percutaneous coronary intervention in New Tokyo Hospital between
January 2004 and December 2012. Of the total, we identiﬁed 238 (1.38%) patients
with coronary perforation. We then evaluated their mid-term clinical outcomes. The
study endpoints were major adverse cardiac events (MACEs), deﬁned as cardiac
death, myocardial infarction (MI), and target lesion revascularization (TLR).
Furthermore, individual parameters, including all-cause death, cardiac death, MI, TLR
and stent thrombosis (ST) during the follow-up period, were evaluated.
Results: Among the 238 patients with coronary perforation, 42 (17.6%) were treated
with PTFE-covered stents. All patients were followed-up for over 6 months (median
follow-up period, 1015 days; interquartile range, 401–1739 days). Although the all-
cause death rate was relatively high, at 11.9% because of complications associated
with coronary perforation, the cardiac death rate was 2.6% at 1 year (Figure). TLR
occurred in 5 patients, and it occurred within 3 months in 3 of these patients. MI
occurred in 1 patient because of side branch occlusion following PTFE-covered stent
implantation. No deﬁnite or probable ST was found.PMI 13 (7.3) 12 (6.6) 0.7 (-4.6 to 6.0) 0.79
Clinically
indicated TVR
Any 7 (3.9) 8 (4.4) -0.5 (-4.6 to 3.7) 0.83
Patient-oriented
composite
end-point
31 (17.3) 31 (16.9) 0.4 (-7.4 to 8.2) 0.92
Deﬁnite ST
(0-720 days)
1 (0.6) 1 (0.5) 0.0 (-1.5 to 1.5) 0.99
Deﬁnite or
probable ST
(0-720 days)
2 (1.1) 1 (0.5) 0.6 (-1.3 to 2.4) 0.55
Very late deﬁnite
or probable
ST (361-720)
1 (0.6) 1 (0.6) 0.0 (-1.5 to 1.5) 0.99
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Background: The aim of this study was to investigate safety and efﬁcacy of second-
generation zotarolimus-eluting Resolute stents and everolimus-eluting Xience V stents
in bifurcation lesions.
Methods: In TWENTE – a prospective, randomized DES trial – PCI patients were
randomized for treatment with contemporary Resolute or Xience V stents. Clinical
endpoints were adjudicated by an external independent clinical events committee
(Cardialysis CRO, Rotterdam, The Netherlands). Target vessel failure (TVF; cardiac
death, target vessel-related myocardial infarction, and clinically-indicated target vessel
revascularization), the primary endpoint of the TWENTE trial, was assessed after 2
years.
Results: Among the 1,391 patients of the TWENTE trial, 362 (26%) patients were
treated for at least one bifurcation lesion. Of these patients, 179 and 183 were
randomized for treatment with Resolute and Xience V stents, respectively. At 2-year
follow-up, TVF (12.8% vs. 11.5%; p¼0.69) and a patient-oriented composite endpoint
(17.3% vs. 16.9%; p¼0.92) did not differ signiﬁcantly between stent arms. In addi-
tion, rates of deﬁnite and or probable stent thrombosis were low and similar for both
stent arms (0.6% vs. 0.5%; p¼0.99). Within 213 (15.3%) patients, who were treated
for bifurcation lesions with an additional treatment of the side-branch, there was also
no signiﬁcant difference in TVF between patients treated with Resolute (n¼98) and
Xience V (n¼115) (8.2% vs. 11.3%; p¼0.44).
Conclusions: Treatment of bifurcation lesions with Resolute and Xience V stents
resulted in favorable and similar outcomes after 2 years in the randomized TWENTE
trial.acts/POSTER/Bare Metal and Drug-Eluting Stent Studies B61
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